By Dean Seal
CV Sciences has agreed to acquire fellow CBD products maker Extract Labs for $1 million in newly issued common stock and $400,000 in cash.
The San Diego-based company said Thursday that the acquisition should grow its sales and client base.
Under the terms of the deal, the sellers of Extract Labs are eligible to receive up to $600,000 in additional CV Sciences stock if certain revenue targets are satisfied in the next two years.
The acquisition is expected to close in the first quarter.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 21, 2024 16:58 ET (21:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.